
Dutch company Staten Biotechnology retains its independence as Novo Nordisk has decided not to exercise an option to acquire both the company and its lead candidate, STT-5058, the Danish pharmaceutical company reports in its financial report on Wednesday.
The two firms partnered up in 2018 to develop STT-5058, which is a monoclonal antibody that Staten Biotechnology inlicensed from Dutch-Belgian company Argenx, which is a collaborator of Leo Pharma.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app